Co-Principal Investigators: Sandra Strauss, MD, PhD University College London Rashmi Chugh , MD
ESP1/SARC025. ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide in Patients with Previously Treated, incurable Ewing Sarcoma. Co-Principal Investigators: Sandra Strauss, MD, PhD University College London
216 views • 10 slides